A Study of LY2603618 in Combination With Gemcitabine in Participants With Solid Tumors
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety and tolerability of LY2603618
in combination with the standard dose of gemcitabine up to the global recommended dose of
LY2603618 in Japanese participants with solid advanced or metastatic tumors.